الأربعاء 10 جمادى الأولى 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patients with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | Ultragenyx Pharmaceutical Inc | Ongoing | UX007/triheptanoin, Medium-chain Triglycerides (MCT),Dextrose. Monosaccharide. Blood Glucose-Elevating Agents. | 3 | UX007-CL30 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A non-interventional, multinational,observational study with isatuximabin patients with relapsed and/orrefractory multiple myeloma (RRMM) | Sanofi | Ongoing | SARCLISA® ( isatuximab - irfc ) | 4 | OBS16577 | Mouwasat Hospital (Dammam),King Faisal Specialist Hospital and Research Center (Jeddah),King Abdulaziz Medical City NG (Jeddah),King Abdulaziz Medical City NG (Riyadh) |
| International collaborative treatment protocol for infants under one year with KMT2Arearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia (Interfant-21) | King Abdullah International Medical Research Center (KAIMRC) | Ongoing | BLINATUMOMAB | 3 | SCT22R/016/12 | King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Medical City NG (Jeddah) |
| An Open label, Single Center, prospective interventional, phase II clinical trial to evaluate the Efficacy and Safety of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine(BV-AVD) combination escalation in advanced stage classical Hodgkin lymphoma patients who did not achieve interim Positron Emission Tomography (PET2) negativity (defined as Deauville score 3 or less) after 2 cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) | King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia | Rejected | BRENTUXIMAB VEDOTIN, DACARBAZINE, VINBLASTINE, DOXORUBICIN HYDROCHLORIDE | 2 | 1 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum | Cristcot HCA LLC | Ongoing | Hydrocortisone Acetate 90 mg | 3 | CHS1221 | King Abdulaziz Medical City NG (Jeddah),King Abdulaziz University Hospital (Jeddah),King Fahad Medical City (Riyadh) |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB | Roche | Rejected | ATEZOLIZUMAB, SORAFENIB | 3 | MO42541 | King Abdulaziz Medical City NG (Riyadh) |
| A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) | AstraZeneca | Ongoing | Lenvatinib (Lenvima) + Durvalumab (Imfinzi) + Tremelimumab (Imjudo) | 3 | D910VC00001 | King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh) |
| A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA) | AstraZeneca | Ongoing | Tozorakimab (MEDI3506) | 3 | D9185C00001 | King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | Boehringer Ingelheim Middle East & North Africa | Ongoing | BI 1015550 | 3 | 1305-0023 | King Faisal Specialist Hospital and Research Center (Riyadh) , King Abdulaziz Medical City NG (Riyadh) , King Abdulaziz University Hospital (Jeddah),King Fahad Specialist Hospital (Dammam) |
| A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST) | Biogen Idec Research Limited | Ongoing | BIIB059 | 2/3 | 230LE301 | King Faisal Specialist Hospital and Research Center (Riyadh) , King Khalid University Hospital (Riyadh) |
تاريخ آخر تحديث: 06/10/2026 بتمام الساعة 08:14 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.